Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
100%(3 trials)

Phase Distribution

Ph phase_3
2
67%
Ph phase_2
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (33.3%)
Phase 32 (66.7%)

Trials by Status

completed3100%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_2

BI 671800 ED in Steroid-naive Asthmatic Patients

NCT01092143
completedphase_3

Mometasone Furoate Aqueous (MK-0887/SCH 032088) Nasal Spray vs Placebo and FLONASE® in Seasonal Allergic Rhinitis Patients (I94-001)

NCT03882047
completedphase_3

A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects

NCT02094937

Clinical Trials (3)

Showing 3 of 3 trials
NCT01092143Phase 2

BI 671800 ED in Steroid-naive Asthmatic Patients

Completed
NCT03882047Phase 3

Mometasone Furoate Aqueous (MK-0887/SCH 032088) Nasal Spray vs Placebo and FLONASE® in Seasonal Allergic Rhinitis Patients (I94-001)

Completed
NCT02094937Phase 3

A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3